EUVIMEDEUVIMED entdecken
Crossref

Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy

Benjamin Blaske, Michael Ward, Ragesh Babu Thandassery

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.124224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Benjamin Blaske und 2 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver condition worldwide, affecting an estimated one-quarter to one-third of the global adult population. Once conceptualized primarily as a hepatic disorder, MASLD is now recognized as a systemic metabolic disease with broad extra-hepatic consequences. Among the most clinically significant of these is a rising body of evidence linking MASLD to an increased risk of malignancies outside the liver. This review synthesizes current evidence on extra-hepatic cancers in MASLD, organized into two categories: Gastrointestinal (GI)-related malignancies and non-GI malignancies. We discuss the shared oncogenic mechanisms underlying these associations, including insulin resistance, chronic inflammation, lipotoxicity, gut microbiome dysbiosis, and adipokine dysregulation. Emerging data demonstrates rising trends in extra-hepatic cancer burden in MASLD populations, with particular concern for young-onset disease and advanced hepatic fibrosis as risk-amplifying factors. We also address current diagnostic gaps and the clinical imperative for developing MASLD-specific cancer surveillance strategies.

Zitieren

APA

Blaske, B., Ward, M., & Thandassery, R. B. (2026). Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.124224

Vancouver

Blaske B, Ward M, Thandassery RB. Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.124224

BibTeX
@article{Blaske2026,
  author = {Blaske, Benjamin and Ward, Michael and Thandassery, Ragesh Babu},
  title = {Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.124224}
}
Kostenlos starten →